Solanezumab fails Phase III clinical trial against Alzheimer’s disease

Written by Lauren Pulling

Eli Lilly and Company (IN, USA) have today announced that the monoclonal antibody solanezumab has not met the primary endpoint in the EXPEDITION3 clinical trial. The Phase III trial was studying the use of solanezumab in patients with mild dementia due to Alzheimer’s disease (AD). EXPEDITION3 is a multinational, Phase III trial of solanezumab in over 2100 patients diagnosed with mild dementia due to AD. The study included an 18-month placebo-controlled period followed by an open-label extension, and is the first Phase III trial to evaluate only individuals with mild dementia due to AD. While some study results, including several secondary...

To view this content, please register now for access

It's completely free